Antimalarial chloroquine indicated for viral infections: myth ou hope?
DOI:
https://doi.org/10.33448/rsd-v10i10.18220Keywords:
COVID-19; Chloroquine; Hydroxychloroquine.Abstract
Aim: this article describes the use of chloroquine as an antimalarial agent with potential antivirotic indications for COVID-19 infections. Methods: On line searches and gray literature have been used in the construction of this articles, whose database include PUBMED Central, BVS/BIREME, Web of Science, Science Direct, Higher Level Personnel Improvement Coordinator (CAPES), Periodic Door (Portal de Periódicos da CAPES, The Cochrane Library and PROSPERO). Results: chloroquine and hydroxychloroquine has shown appropriate clinical reports when associated with the antibiotic Azithromycin. It has been authorized for the clinical treatment of grave acute forms of COVID infections by countries like Brazil and USA. Conclusions: Chloroquine seems to have potential antivirotic properties that may be useful in the treatment of the grave acute forms of COVID-19 associated with Azithromycin. Nevertheless, Its indication must include ECG monitoring due to the risk of cardiac QT prolongation able to cause sudden deaths.
References
«柳叶刀披露首例新冠肺炎患者发病日期，较官方通报早7天». BJ News.
Al-Bari, M. A. (2017). "Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases". Pharmacology Research and Perspectives. 5 (1): e00293. doi:10.1002/prp2.293. PMC 5461643. PMID 28596841.
Allison, J. L., Brien, R. L. O’ & Hahn, F.E. (1966). Nature of the Deoxy Ribonucleic Acidchloroquine complex. In Antimicrobial agents and chemotherapy Sylverster, J.C; ed. American Society for Microbiology, Ann. Arbor. Mich. Pp. 310-314. 10.1128/aac.5.3.310
Bagnall, A. The value of chloroquine in rheumatoid disease. A four-year study of continuous therapy. Can Med Assoc J, 1957, 77, 182–194.
Berliner, R. W., Earle, D. P., Taggart, J. V., Zubrodder, S. T., Welch, W. J., Conan, N. J., Bauman, E., Scudder, S. T., & Shannon, J. A. Studies on the chemotherapy of the human malarias. VI. The physiological disposition, antimalarial actifity, and toxicity of several derivatives of 4-aminoquinoline. J. Clin.Invest. 1948, 27, 98-107.
Bruce-Chwatt, L. J. EmMalaria: Principles and Practice of Malariology;Wernsdorfer, W. H.; McGregor, I,eds.; Churchill Livingstone: Edinburgh, 1988, 1-59.
Carlson, J., Helmby, H., Hill, A., Brewster, D., Greenwood, B. & Wahlgren, M. (1990). Human cerebral malaria: association with erytbrocyterosetting and lack of anti-rosetting antibodies. Lancet, 336, 1457-1460.
Cohen, S. N., & Yielding.K. L. 1965. Inhibition of DNA and RNA polymerase reactions by chloroquine. Proc. Nat. Acad. Sci. U.S.A. 54:521-527
Chew, C. Y. et al. Hydroxychloroquine in dermatology: New perspectives on an old drug. The Australasian College of Dermatologists, n. 2, 2019. https://revistas.unijui.edu.br/index.php/contextoesaude/article/download/10393/6369
Cortegiani, A., Ingoglia, G., Ippolito, M., Giarratano, A., & Einav S (2020). "A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19". Journal of Critical Care. doi:10.1016/j.jcrc.2020.03.005.
«Coronavirus disease (COVID-19) outbreak» . Organização Mundial da Saúde.
Davidson, M. W. Antimalarial action of quinoline methanolamines as mefloquine, quinacrine, chloroquine and quinine does not involve interaction with DNA, reported results from laboratory study. J. Med. Chem, 20 (9), 1117-1122 (1977).
Dubois, E. L. Antimalarials in the management of discoid and systemic lupus arythematosus. Semin Arthritis Rheum. 1978;8:33-51.https://doi.org/10.1016/0049-0172(78)90033-1
Fern, Ken (2010–2020). "Cinchona officinalis – L." Plans for a Future.
Foye, W. O.; Lemke, T. L.; & Williams, D. A.; Principles of Medicinal Chemistry, (4th ed.), Williams & Wilkins: 1995.
Fredericksen, B. L., Wei, B. L., Yao, J., Luo, T., & Garcia, J. V. (November 2002). "Inhibition of endosomal/lysosomal degradation increases the infectivity of human immunodeficiency virus". Journal of Virology. 76 (22): 11440–6. doi:10.1128/JVI.76.22.11440-11446.2002. PMC 136743. PMID 12388705.
Garnham, P. C. C. 1966. Malaria parasites and other haemosporidia. Blackwell Scientific Publications, Oxford, United Kingdom. Google Scholar.
Haeusler, I. L.; Chan, X. H. S.; Guérin, X. H. S.; Guérin, P. J.; & White, N. J. The arrhythmogenic cardiotoxicity of the Quinoline and structurally related antimalarial drugs: A systematic review. BMC Med, 16(1), 200. 2018.
Inder, R. M. -Malaria; the design, use, and mode of action of chemotherapeutic agents. Dorchester, Scientechnica, Dorset, 1973.316 p.
Isaacson, D., Elgart, M., & Turner, M. L. Antimalarials in dermatology. Int J Dermatol. 1982;21:379-95.
January, C., & Riddle, J. (1989) Early after depolarizations: mechanism of induction and block. A role for L-type Ca2+ current. Circ Res64: 977–990 [PubMed] [Google Scholar]
Krafts, K., Hempelmann, E., & Skórska-Stania, A (2012). "From methylene blue to chloroquine: a brief review of the development of an antimalarial therapy". Parasitology Research. 111 (1): 1–6.
National Center for Biotechnology Information, 2019. The United States National Library of Medicine. https://doi.org/10.1007/s00436-012-2886-x
Novel Coronavirus Pneumonia Emergency Response Epidemiology Team (February, 2020). «[The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]». Zhonghua Liu Xing Bing XueZaZhi=ZhonghuaLiuxingbingxueZazhi (emchinês). 41 (2): 145–151. 10.3760/cma.j.issn.0254-6450.2020.02.003
Organizacion Mundial De La Salud -Terminologiadeipaludismo y de Iaerradicacióndeipaludismo. 1964.p.122.
Orolkovas, A. -Mecanismo de ação dos antimaláricos. Rev. bras. Clin. Terap., , 4 (5): 183-186,1975.
Peters, W. -Chemotherapy and drug resistance in malaria. Ipswich, Academic Press, 1970. 876 p.
Pinder, R. M. -Malaria; the design, use, and mode of action of chemotherapeutic agents. Dorchester, Scientechnica, Dorset, 1973.316 p
Plowe, C. V. (2005). "Antimalarial drug resistance in Africa: strategies for monitoring and deterrence". Malaria: Drugs, Disease and Post-genomic Biology. Current Topics in Microbiology and Immunology. 295. pp. 55–79. doi:10.1007/3-540-29088-5_3. ISBN 3-540-25363-7. PMID 16265887.
Powell, S. J. Therapy of amebiasis. Bull NY Acad Med 47:469-477, 1971
Rainsford, K. D., Parke, A. L., Clifford-Rashotte, M. & Kean, W. F. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology. 2015;23(5):231-69.
Rey, L. D. ECT QT interval prolongation in reumathic patients using antimalarial drugs. Rev. Bras. REumatol. (on line). 2003. Vol.43, n.5, pp.275-278. ISSN 0482-5004. https://doi.org/10.1590/S0482-5004200300500003.
Rockwell, D A. Psychiatric complications with chloroquine and quinacrine. Am J Psychiatry. 1968;124(9):1257-60.
Rowe, A., Obiero, J., Newbold, C. & Marsh, K. (1995). Plasmedium falciparum rosetting 1s associated with malaria severity in Kenya. Infection and Immunity, 63,2323-2326.
Rynes, R. I. Antimalarial drugs in the treatment of rheumatological diseases. Br J Rheumatol. 1997;36(7):799-805. Comment in: Br J Rheumatol. 1998;37(5):580.
Savarino, A., Boelaert, J. R., Cassone, A, Majori, G, & Cauda R (November 2003). "Effects of chloroquine on viral infections: an old drug against today's diseases?". The Lancet. Infectious Diseases. 3 (11): 722–7.https://doi.org/10.1016/S1473-3099(03)00806-5
Schellenberg, K. A., & Coatney, G. R. Biochem, Pharmacol. 6, 143 (1960).
Smith, T., Bushek, J., & Prosser, T. COVID-19 Drug therapy – Potential Options. Elsevier.
«Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV)» . OMS.
Rowe, A., Obiero, J., Newbold, C. Chou, A. C., & Fitch, C. D. (1980) Hemolysis of mouse erythrocytes by ferriprotoporphyrin IX and chloroquine: Chemotherapeutic implications. J Clin Invest 66:856-858. https://doi.org/10.1016/0140-6736(90)93174-N
Steck, E. A. -Chemotherapy of malaria. In: The chemotherapy of protozoan diseases. (Washington). Walter Reed Army I nstitute of Research, (1971). Vol. 3, Capo2 3. 376p.
Temin, H. M. The DNA provirus hypothesis-The Establishment and Implications of RNA-directed DNA Synthesis. Physiology or Medicine. University of Wisconsin, Madison, Wisconsin, USA. 1975.
Udomsangpetch, R., Thanikkul, K., Pukrittayakamee, S. & White, N. J. (1995). Rosette formation by Phmodium&ax. Transactions of the Royal Society of Tropical Medicine and Hygiene, 89, 635-637.
Verbeeck, R. K.; Junginger, H. E.; Midha, K. K.; Shah, V. P.; & Barends, D. M. Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms Based on Biopharmaceutics Classification System (BCS) Literature Data: Chloroquine Phosphate, Chloroquine Sulfate, and Chloroquine Hydrochloride. J Pharm Sci 94:1389–1395, 2005.
W. Sneader: Drug Discovery. a history. wiley, https://doi.org/10.1016/0035-9203(95)90422-0
Wallace, D. J. Antimalarial agents and lupus. Rheum Dis Clin North Am. 1994; 20(1): 243-63. Review.
White, N. J. (2008). Plasmodium knowlesi: the fifth human malaria parasite. Clin. Infect. Dis. 46:172–173. CrossRefPubMedWeb of ScienceGoogle Scholar. https://doi.org/10.1016/S0889-857X(21)00233-7
Zhang, T. et al. Clinical trials for the treatment of Coronavírus disease 2019 (COVID-19): A rapid response to urgent need. Science China life Sciences, n. 12, https://revistas.unijui.edu.br/index.php/contextoesaude/article/download/10393/6369
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Guilherme Marinho Sampaio; Gabriel Henrique Queiroz Oliveira; Hadassa Fonsêca Silva; Alice Pinho André Gomes Morais; Jatiacynan Andrade Souza; William José Lopes Freitas; Paulo Melo Júnior; Sandra Sayão Maia; João Henrique Santos Silva; Juliana Mariano Carvalho Azevedo; Rodolfo Scavuzzi Carneiro Cunha; Sheyla Priscila Madeira Melo; Luisa Manuela Pomba Samba; Caroline Isabele Félix Muniz; Marcela Nogueira Santos; Luciano Barreto Silva
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
